Case Control Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Feb 14, 2020; 26(6): 627-644
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.627
Figure 5
Figure 5 Rescue experiment. A: Cell proliferation ability after transfection with miR-19a-3p-mimics + sh-Forkhead box F2 (FOXF2) or miR-19a-3p-inhibitor + si-FOXF2; B: Cell invasion ability after transfection with miR-19a-3p-mimics + sh-FOXF2 or miR-19a-3p-inhibitor + si-FOXF2; C: Cell migration ability after transfection with miR-19a-3p-mimics + sh-FOXF2 or miR-19a-3p-inhibitor + si-FOXF2; D: Expression of p-GSK-3β, β-catenin, α-catenin,, GSK-3β and p-β-catenin in cells transfected with miR-19a-3p-mimics + sh-FOXF2 or miR-19a-3p-inhibitor + si-FOXF2; E: Western blot map; F: Expression of E-cadherin, N-cadherin, and vimentin in cells transfected with miR-19a-3p-mimics+sh-FOXF2 or miR-19a-3p-inhibitor+si-FOXF2; G: Western blot map; aP < 0.05 vs cells transfected with miR- negative control or miR-19a-3p-mimics + sh-FOXF2 or with cells transfected with miR-19a-3p-inhibitor+si-FOXF2, bP < 0.001 vs cells transfected with miR-19a-3p-inhibitor. FOXF2: Forkhead box F2.